Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

646 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis.
Bertrand MJ, Tardif JC. Bertrand MJ, et al. Among authors: tardif jc. Expert Opin Emerg Drugs. 2017 Mar;22(1):1-26. doi: 10.1080/14728214.2017.1269743. Epub 2016 Dec 22. Expert Opin Emerg Drugs. 2017. PMID: 27927063 Review.
Biocompatibility aspects of new stent technology.
Bertrand OF, Sipehia R, Mongrain R, Rodés J, Tardif JC, Bilodeau L, Côté G, Bourassa MG. Bertrand OF, et al. Among authors: tardif jc. J Am Coll Cardiol. 1998 Sep;32(3):562-71. doi: 10.1016/s0735-1097(98)00289-7. J Am Coll Cardiol. 1998. PMID: 9741494 Review.
Effect of a short-term primary prevention program on endothelium-dependent vasodilation in adults at risk for atherosclerosis.
Jodoin I, Bussières LM, Tardif JC, Juneau M. Jodoin I, et al. Among authors: tardif jc. Can J Cardiol. 1999 Jan;15(1):83-8. Can J Cardiol. 1999. PMID: 10024863 Review.
Insights into oxidative stress and atherosclerosis.
Tardif JC. Tardif JC. Can J Cardiol. 2000 Jul;16 Suppl D:2D-4D. Can J Cardiol. 2000. PMID: 10932028 Review.
Design features of the Avasimibe and Progression of coronary Lesions assessed by intravascular UltraSound (A-PLUS) clinical trial.
Tardif JC, Grégoire J, Lespérance J, Lambert J, L'Allier PL, Rodés J, Anderson T, Blue JW, Imus J, Heinonen T. Tardif JC, et al. Am Heart J. 2002 Oct;144(4):589-96. doi: 10.1067/mhj.2002.125329. Am Heart J. 2002. PMID: 12360153 Clinical Trial.
Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).
Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC; Studies Of Left Ventricular Dysfunction. Vermes E, et al. Among authors: tardif jc. Circulation. 2003 Mar 11;107(9):1291-6. doi: 10.1161/01.cir.0000054611.89228.92. Circulation. 2003. PMID: 12628950
Clinical results with AGI-1067: a novel antioxidant vascular protectant.
Tardif JC. Tardif JC. Am J Cardiol. 2003 Feb 6;91(3A):41A-49A. doi: 10.1016/s0002-9149(02)03149-1. Am J Cardiol. 2003. PMID: 12645643 Review.
Absence of association between infectious agents and endothelial function in healthy young men.
Khairy P, Rinfret S, Tardif JC, Marchand R, Shapiro S, Brophy J, Dupuis J. Khairy P, et al. Among authors: tardif jc. Circulation. 2003 Apr 22;107(15):1966-71. doi: 10.1161/01.CIR.0000064895.89033.97. Epub 2003 Apr 7. Circulation. 2003. PMID: 12681997
Pharmacologic prevention of both restenosis and atherosclerosis progression: AGI-1067, probucol, statins, folic acid and other therapies.
Tardif JC, Grégoire J, Lavoie MA, L'Allier PL. Tardif JC, et al. Curr Opin Lipidol. 2003 Dec;14(6):615-20. doi: 10.1097/00041433-200312000-00010. Curr Opin Lipidol. 2003. PMID: 14624139 Review.
Prevention of restenosis with antioxidants: mechanisms and implications.
Tardif JC, Grégoire J, L'Allier PL. Tardif JC, et al. Am J Cardiovasc Drugs. 2002;2(5):323-34. doi: 10.2165/00129784-200202050-00005. Am J Cardiovasc Drugs. 2002. PMID: 14727962 Review.
646 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback